阿德福韦酯与拉米夫定治疗乙型肝炎肝硬化的疗效探讨

目的探讨阿德福韦酯(ADV)与拉米夫定(LAM)治疗乙型肝炎肝硬化的临床疗效和安全性。方法选取乙型肝炎肝硬化患者86例,分为两组,各43例。对照组给予常规保肝治疗,观察组给予ADV和LAM治疗,均连续24周。治疗前后观察肝功能、HBV-DNA定量和不良反应情况。结果观察组与对照组总有效率为90.70%和79.07%,差异有统计学意义(P<0.05)。治疗后,两组患者ALT、TbiL、HBV-DNA均较治疗前改善,且观察组改善程度优于对照组,差异有统计学意义(P<0.01)。观察组与对照组不良反应发生率分别为6.98%和4.65%,差异无统计学意义(P>0.05)。结论阿德福韦酯与拉米夫定治疗乙型肝炎肝硬化具有疗效明确,快速清除病毒,安全性高等特点,值得基层医疗机构推广应用。

Objective To explore the effect and safety of treating hepatitis b cirrhosis by Adefovir （ADV） and Lamivudine （LAM）.Methods 86 patients with hepatitis b cirrhosis were selected,and divided into observation group and control group,43 cases per group.Patients in control group were given conventional treatment,yet patients in observation group were given ADV and LAM,and they were all treated for 24 weeks.Liver function,HBV DNA quantitative and adverse reaction were tested before and after treatment.Results Total effective rate in observation group and control group were 90.70% and 79.07% （P0.05）. Liver function and HBV DNA quantitative in two groups were improved after treatment （P0.05）,and observation group’s effect was superior than that of control group（P0.01）.Adverse reaction rate in observation group and control group were 6.98% and 4.65% （P0.05）.Conclusion It has high clinical efficiency of treating hepatitis b cirrhosis by ADV and LAM,and it eliminates HBV rapidly,also with higher security,so it is suitable for hepatitis b cirrhosis’s clinical treatment.